Study limitation: Cloxacillin was dosed at 12 g/day without renal adjustment; the AKI signal may not generalize to lower doses or renally adjusted regimens | ReachRx
Benzylpenicillin versus flucloxacillin or cloxacillin for the treatment of penicillin-susceptible Staphylococcus aureus bacteraemia (SNAP): an international, multicentre, open-label, non-inferiority randomised controlled trial
Study limitation reported by the research below: “Cloxacillin was dosed at 12 g/day without renal adjustment; the AKI signal may not generalize to lower doses or renally adjusted regimens.”
